OPTiM Oncovex GM-CSF Pivotal Trial in melanoma

BioVex.com

Contact Us

OPTiM - Testing a New Approach in Advanced Melanoma. OPTiM is a Phase 3 clinical study evaluating a new investigational agent called OncoVEXGM-CSF.
            
            
            
Image © iStockphoto.com

For questions related to the OPTiM trial or OncoVEXGM-CSF
contact Amgen Medical Information:1-800-77-AMGEN (1-800-772-6436)

Additional details are available here at clinicaltrials.gov

 

© 2011 Amgen Inc. All Rights Reserved | Privacy & Terms